# A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

> **NCT05059301** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 770 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSVPreF3 OA investigational vaccine

## Key facts

- **NCT ID:** NCT05059301
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-01
- **Primary completion:** 2022-01-24
- **Final completion:** 2022-06-30
- **Target enrollment:** 770 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059301, "A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05059301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*